Angiotensin-converting Enzyme (ACE) Inhibitor

(R,R)-Benazepril is the R configuration of Benazepril (HY-B0093). Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor that reduces the production of angiotensin II. Benazepril inhibits oxidative stress and suppresses apoptosis through the PI3K/Akt signaling pathway. Benazepril effectively ameliorates diabetic nephropathy and reduces proteinuria. Benazepril is used in the study of hypertension, heart failure, and diabetic nephropathy.

SQ 27786 is an angiotensin converting enzyme (ACE) inhibitor and a diuretic agent. SQ 27786 can be utilized in cardiovascular disease research.

Utibaprilat (FPL 63674XX) is a ACE inhibitor that is a major degradation product of Utibapril (HY-101681).

Pentoprilat (CGS 13934) is an orally active angiotensin-converting enzyme (ACE) inhibitor and is the active metabolite of Pentopril (HY-187790). Pentoprilat acts as a substrate for renal tubular secretion. Pentoprilat is rapidly excreted in urine via the kidneys in its unchanged form. Pentoprilat can be used in related studies on hypertension and congestive heart failure.

Imidapril-d₃ hydrochloride (TA-6366-d₃) is the deuterium labeled Imidapril hydrochloride. Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions.

YM-1 (TFA) is an inhibitor of angiotensin converting enzyme (ACE) that can be obtained from Chrysanthemum boreale Makino.

Benazepril (Standard) is the analytical standard of Benazepril. This product is intended for research and analytical applications. 0

Perindopril-d₅ (S-9490-d₅) is deuterium labeled Perindopril. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension.

Antiviral agent 46 (compound 4) is a derivative of cannabidiol (CBD) with anti-SARS-CoV-2 (IC₅₀: 1.90 μM) and ACE2 activity (IC₅₀: 1.37 μM).

Quinapril-d₄ (CI-906-d₄) is deuterium labeled Quinapril. Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models.

Temocapril-d₅ is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.

Cilazapril (monohydrate) (Standard) is the analytical standard of Cilazapril monohydrate (HY-A0043A). This product is intended for research and analytical applications. Cilazapril monohydrate is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril monohydrate reduces plasma ACE activity. Cilazapril monohydrate can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure.

Glycosyltransferase-IN-2 (Compound 20) is a Glycosyltransferase inhibitor. Glycosyltransferase-IN-2 has a broad-spectrum anticoronavirus activity with IC₅₀s of 11.3, 5.5 and ~16.2 μM for MHV, HCoV-NL63 and SARS-CoV-2, respectively. Glycosyltransferase-IN-2 interferes with the coronavirus infectivity, alters viral protein glycosylation with inhibition of interaction with the ACE2 receptor or SC-VLP secretion, and inhibits RNA replication. Glycosyltransferase-IN-2 can be used for coronavirus infections research.

SARS-CoV-2-IN-116 (Compound (S,S)-4) is a highly selective angiotensin-converting enzyme 2 (ACE2) inhibitor (pIC₅₀=7.61). SARS-CoV-2-IN-116 blocks the interaction between SARS-CoV-2 spike protein and ACE2. SARS-CoV-2-IN-116 is promising for research of COVID-19.

Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

Rentiapril racemate (SA-446 racemate) is the racemate of Rentiapril. Rentiapril is an angiotensin converting enzyme (ACE) inhibitor.

SQ 20858 is a competitive Angiotensin-converting enzyme inhibitor. SQ 20858 blocks the conversion of Angiotensin I to Angiotensin II, inhibits the inactivation of Bradykinin (HY-P0206) and amplifies the hypotensive response of Bradykinin. SQ 20858 blocks the pressor responses of Angiotensin I and rabbit Renin, but has no effect on the pressor effect of angiotensin II . SQ 20858 reduces blood pressure in renal hypertension models. SQ 20858 can be used in studies related to chronic renal hypertension.

Ser-Ala-Pro is an X-Pro structure specific angiotensin-converting enzyme (ACE) inhibitory peptide. Ser-Ala-Pro has the potential for hypertension research.

BML-111 (Standard) is the analytical standard of BML-111 (HY-100450). This product is intended for research and analytical applications. BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties.

Fosinopril-d₅ (SQ28555-d₅ (free acid)) is deuterium labeled Fosinopril. Fosinopril (SQ28555 free acid) is the ester proagent of angiotensin-converting enzyme (ACE) inhibitor with an IC₅₀ value of 0.18 μM. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with an K_i value of 1.675 μM.